site logo

Apellis eye drug succeeds in one key study, but falls short in its twin

Study results showed divergent outcomes for Apellis' therapy in treating a form of vision loss. Even so, the company plans to ask for FDA approval.

Courtesy of Apellis Pharmaceuticals